Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.

Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP.

Mol Ther Oncolytics. 2018 Oct 18;11:62-74. doi: 10.1016/j.omto.2018.10.001. eCollection 2018 Dec 21.

2.

Please stand by: how oncolytic viruses impact bystander cells.

Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP.

Future Virol. 2018 Sep;13(9):671-680. doi: 10.2217/fvl-2018-0068. Epub 2018 Aug 8. Review.

PMID:
30416535
3.

Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.

Ghonime MG, Cassady KA.

Cancer Immunol Res. 2018 Dec;6(12):1499-1510. doi: 10.1158/2326-6066.CIR-18-0014. Epub 2018 Oct 23.

PMID:
30352799
4.

Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease.

Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K.

J Pediatr. 2018 Oct;201:274-280.e12. doi: 10.1016/j.jpeds.2018.05.033. Epub 2018 Jul 2.

PMID:
30041935
5.

High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.

Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP.

Viruses. 2018 Mar 15;10(3). pii: E132. doi: 10.3390/v10030132.

6.

Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory.

Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA.

Transl Oncol. 2018 Feb;11(1):86-93. doi: 10.1016/j.tranon.2017.10.005. Epub 2017 Dec 18.

7.

Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.

Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM.

Mol Ther Oncolytics. 2017 Mar 1;5:1-10. doi: 10.1016/j.omto.2017.02.001. eCollection 2017 Jun 16.

8.

Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Foreman PM, Friedman GK, Cassady KA, Markert JM.

Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Review.

9.

STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.

Jackson JD, Markert JM, Li L, Carroll SL, Cassady KA.

Mol Cancer Res. 2016 May;14(5):482-92. doi: 10.1158/1541-7786.MCR-15-0427. Epub 2016 Feb 16.

10.

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.

Cassady KA, Haworth KB, Jackson J, Markert JM, Cripe TP.

Viruses. 2016 Feb 4;8(2). pii: E43. doi: 10.3390/v8020043. Review.

11.

Encouraging Antibiotic Development and Endorsing Conservation: Tandem Approaches to Our Declining Antibiotic Reserves.

Cassady KA, Newland JG, Saiman L.

Infect Control Hosp Epidemiol. 2016 Mar;37(3):366-7. doi: 10.1017/ice.2015.329. Epub 2016 Jan 6. No abstract available.

PMID:
26732605
12.

γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.

Friedman GK, Nan L, Haas MC, Kelly VM, Moore BP, Langford CP, Xu H, Han X, Beierle EA, Markert JM, Cassady KA, Gillespie GY.

Gene Ther. 2015 Apr;22(4):356. doi: 10.1038/gt.2015.5. No abstract available.

PMID:
25832732
13.

γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.

Friedman GK, Nan L, Haas MC, Kelly VM, Moore BP, Langford CP, Xu H, Han X, Beierle EA, Markert JM, Cassady KA, Gillespie GY.

Gene Ther. 2015 Apr;22(4):348-55. doi: 10.1038/gt.2014.107. Epub 2014 Nov 27. Erratum in: Gene Ther. 2015 Apr;22(4):356.

14.

Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.

Jackson JD, McMorris AM, Roth JC, Coleman JM, Whitley RJ, Gillespie GY, Carroll SL, Markert JM, Cassady KA.

Gene Ther. 2014 Nov;21(11):984-90. doi: 10.1038/gt.2014.72. Epub 2014 Aug 14.

15.

Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.

Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers NW, Grimes SD, Carroll SL, Gillespie GY, Whitley RJ, Markert JM.

Hum Gene Ther Clin Dev. 2014 Mar;25(1):16-27. doi: 10.1089/humc.2013.201.

16.

Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates.

Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers N, Grimes S, Carroll SL, Gillespie GY, Whitley R, Markert J.

Hum Gene Ther Clin Dev. 2014 Feb 28. [Epub ahead of print]

PMID:
24579875
17.

Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.

Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, Whitley RJ, Parker JN.

PLoS One. 2013 Nov 27;8(11):e81768. doi: 10.1371/journal.pone.0081768. eCollection 2013.

18.

Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.

Friedman GK, Raborn J, Kelly VM, Cassady KA, Markert JM, Gillespie GY.

Front Oncol. 2013 Feb 28;3:28. doi: 10.3389/fonc.2013.00028. eCollection 2013.

19.

Human herpesviridae methods of natural killer cell evasion.

Odom CI, Gaston DC, Markert JM, Cassady KA.

Adv Virol. 2012;2012:359869. doi: 10.1155/2012/359869. Epub 2012 Jul 8.

20.

Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.

Friedman GK, Haas MC, Kelly VM, Markert JM, Gillespie GY, Cassady KA.

Transl Oncol. 2012 Jun;5(3):200-7. Epub 2012 Jun 1.

21.

Targeting pediatric cancer stem cells with oncolytic virotherapy.

Friedman GK, Cassady KA, Beierle EA, Markert JM, Gillespie GY.

Pediatr Res. 2012 Apr;71(4 Pt 2):500-10. doi: 10.1038/pr.2011.58. Epub 2012 Feb 15. Review.

22.
23.

Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation.

Shimamura M, Saunders U, Rha B, Guo L, Cassady KA, George JF, Britt WJ.

Transplantation. 2011 Oct 15;92(7):759-66. doi: 10.1097/TP.0b013e31822c6e89.

24.

Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents.

Parker JN, Zheng X, Luckett W, Markert JM, Cassady KA.

Mol Pharm. 2011 Feb 7;8(1):44-9. doi: 10.1021/mp100230y. Epub 2010 Dec 17. Review.

25.

Herpesvirus vectors for therapy of brain tumors.

Cassady KA, Parker JN.

Open Virol J. 2010 Jun 18;4:103-8. doi: 10.2174/1874357901004030103.

26.

Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response.

Shah AC, Parker JN, Shimamura M, Cassady KA.

Viruses. 2009 Dec;1(3):510-22. doi: 10.3390/v1030510. Epub 2009 Oct 22.

27.

Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.

Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM, Yancey Gillespie G.

J Neurooncol. 2009 Nov;95(2):199-209. doi: 10.1007/s11060-009-9926-0. Epub 2009 Jun 12.

28.

Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma.

Bryan CJ, Prichard MN, Daily S, Jefferson G, Hartline C, Cassady KA, Hilliard L, Shimamura M.

Pediatr Infect Dis J. 2008 Oct;27(10):946-8. doi: 10.1097/INF.0b013e318175d85c.

PMID:
18776818
29.

Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.

Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA.

Gene Ther. 2007 Jul;14(13):1045-54. Epub 2007 Apr 12.

PMID:
17429445
30.

Ulceroglandular tularemia in a nonendemic area.

Guffey MB, Dalzell A, Kelly DR, Cassady KA.

South Med J. 2007 Mar;100(3):304-8. Review.

PMID:
17396737
31.
35.

New Thoughts on Pathogenesis and Diagnosis of Encephalitis.

Cassady KA, Whitley RJ.

Curr Infect Dis Rep. 1999 Jun;1(2):178-186.

PMID:
11095786
38.

New therapeutic approaches to the alphaherpesvirus infections.

Cassady KA, Whitley RJ.

J Antimicrob Chemother. 1997 Feb;39(2):119-28. Review.

PMID:
9069530

Supplemental Content

Loading ...
Support Center